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Background: Several reports have shown an increased prevalence of gastrointestinal (GI)
symptoms in obese subjects in community-based studies.To better understand the role of
the GI tract in obesity, and because there are limited clinic-based studies, we documented
the prevalence of upper and lower GI symptoms in morbidly obese individuals in a clinic
setting.
Objective:The aim of our study was to compare the prevalence of GI symptoms in morbidly
obese individuals in a weight management clinic with non-obese individuals with similar
comorbidities as morbidly obese individuals in an Internal Medicine clinic.
Methods: Class II and III obese patients BMI >35 kg/m2 (N =114) and 182 non-obese
patients (BMI <25 kg/m2) completed the GI symptoms survey between August 2011 and
April 2012 were included in this study.The survey included 24 items pertaining to upper and
lower GI symptoms. The participants rated the frequency of symptoms as absent (never,
rarely) or present (occasionally, frequently). The symptoms were clustered into five cat-
egories: oral symptoms, dysphagia, gastroesophageal reflux, abdominal pain, and bowel
habits. Responses to each symptom cluster were compared between obese group and
normal weight groups using logistic regression.
Results:Of the 24 items, 18 had a higher frequency in the obese group (p<0.005 for each).
After adjusting for age and gender, the obese patients were more likely to have upper GI
symptoms: any oral symptom (OR=2.3, p=0.0013), dysphagia (OR 2.9, p=0.0006), and
any gastroesophageal reflux (OR 3.8, p<0.0001). Similarly, the obese patients were more
likely to have lower GI symptoms: any abdominal pain (OR=1.7, p=0.042) and altered
bowel habits (OR=2.8, p<0.0001).
Conclusion: These observations suggest a statistically significant increase in frequency
of both upper and lower GI symptoms in morbidly obese patients when compared to
non-obese subjects.
Keywords: obesity, gastrointestinal, symptoms, body mass index, clinic-based studies
INTRODUCTION
The obesity epidemic continues unabated world-wide. The
increasing prevalence of overweight and obesity has resulted in
3.4 million deaths, 3.9% of years lost, and 3.8% of disability
adjusted life-years world-wide. Greater than 50% of obese indi-
viduals reside in the USA, China, India, Russia, Brazil, Egypt,
Germany, Pakistan, and Indonesia (1). The USA accounted for
13% of these obese individuals in 2013. Obesity trends in the
USA along with associated comorbidities could, for the first time
result in decreased life expectancy (2). The Centers for Disease
Control, National Center for Health Statistics in the USA, has esti-
mated that, between 2011 and 2012, more than one-third of adults
(34.9%) were obese and that two-thirds of the US population is
overweight or obese (3). The burden of obesity and its associ-
ated health problems have a significant adverse impact on the US
healthcare system. In 2008, the annual healthcare cost in the US
was estimated to be a staggering $ 147 billion (4). Besides cost,
obesity results in 100,000 excess deaths per annum (5) and esti-
mated years of life lost (difference between the number of years
an individual would live if not obese and the number of years
expected to live if obese) was estimated to be 13 years for white men
aged 20 years with BMI >45 kg/m2 and 8 years for white women
aged 20–30 years with BMI>45 kg/m2 compared to normal weight
controls (6).
The gastrointestinal (GI) tract is normally the only site of nutri-
ent and calorie absorption. Improved understanding of the role of
the GI tract in obesity may help develop strategies to decrease
obesity and obesity-related health costs. Because there are limited
clinic-based studies, in contrast to population-based studies, we
documented the prevalence of upper and lower GI symptoms in
morbidly obese individuals attending the Obesity Institute out-
patient clinic and normal weight individuals with similar comor-
bidities attending the General Internal Medicine (GIM) clinic at
the Geisinger Medical Center in Danville, PA, USA.
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SUBJECTS AND METHODS
This study included morbidly obese patients (BMI >35 kg/m2)
with metabolic comorbidities or BMI >40 kg/m2 and normal
weight patients (BMI 18.5–24.9 kg/m2) who sought care at
Geisinger Medical Center, Danville, PA, USA. All potential study
subjects were asked to complete the GI Symptoms survey, which
was developed by the study team to address the frequency of GI
symptoms. The questionnaire included 24 items and was formu-
lated via literature review, review of gastroenterology textbooks
and incorporated the Rome II and III questionnaires. The patients
rated the frequency of symptoms as “Never, Rarely, Occasionally,
and Frequently” (Table 1). The symptoms were categorized into
the following five clusters: (1) oral symptoms – mouth ulcers,
bleeding gums, dental problems, tongue swelling, sour taste; (2)
dysphagia – gagging, trouble swallowing solids or liquids; (3)
reflux – sour taste, nausea, vomiting, heartburn, belching/burping;
(4) abdominal pain – cramping with hunger or post-meal; (5)
bowel habits – diarrhea, fecal urgency and incontinence, bloating,
constipation, excessive flatus, use of laxatives, rectal bleeding.
The obese study group included patients with extreme obesity
that agreed to participate in a separate, ongoing research study
of bariatric surgery within the Nutrition and Weight Manage-
ment Clinic of the Obesity Institute (7). Consecutive patients that
completed the GI Symptoms survey between August 2011 and
April 2012 were included in this research study (N = 114). Dur-
ing the same time period, non-obese patients were recruited from
the GIM clinic. For this study group, potential participants were
identified by querying the Geisinger electronic health record for
patient’s seen in the GIM clinic in the preceding 1 year with a
BMI 18.5–25 kg/m2. The study population was limited to those
aged 18–64 years in both groups. Patients with a prior history of
intra-abdominal surgery, inflammatory bowel disease, any acute
infectious processes, and patients using orlistat were excluded from
the study. The eligible normal weight patients with comorbidities
similar to the obese group (N = 652) were mailed a packet that
included an introduction letter, the GI Symptoms survey, and a
pre-addressed, pre-paid return envelope. Four patient letters were
returned due to wrong address. Of the remaining 648 patients, 140
returned the survey within 6 weeks. The remaining patients were
sent a second packet with a revised introduction letter and the same
survey and envelope. This resulted in an additional 42 completed
surveys, and an overall total of 182 normal weight participants
(overall completion rate of 28%).
Responses to each symptom question were compared between
the normal weight and obese group using Cochran–Armitage
trend tests. For each of the five symptom domain groups, patients
were classified as having any symptom within the group (defined
as “Occasionally” or “Frequently” for any of the questions within
the symptom domain group) or no symptoms (defined as “Never”
or “Rarely” for all of the questions within the symptom group).
In bivariate analysis, the percent of patients with any symptom
was compared between the normal weight and obese groups using
a chi-square test. In multivariate analysis (adjusting for age and
gender), logistic regression was used to measure the association
between the presence of any symptom and obesity status. Separate
regression models were used for each symptom group. To confirm
that categorizing the likert scaled response items into present
(i.e., “Occasionally” or “Frequently”) or absent (i.e., “Never” or
“Rarely”) did not influence the results, the data were reanalyzed
using the likert scale for each question. The categorized version
is presented because these simpler results agreed with the more
complex analysis. SAS version 9.3 was used for statistical analysis
and a p-value <0.05 was considered significant.
Funding for this study was provided through Geisinger inter-
nal funds. The Geisinger Institutional Research Review Board
approved the study.
RESULTS
The 182 normal weight patients had a mean BMI of 22.1 kg/m2
(SD= 1.7), a mean age of 50.8 years (SD= 11.1), and 78% were
female (Table 2). As compared to the 470 non-responders, the
182 normal weight patients that responded to the survey were
older (50.8 years versus 45.0 years, p< 0.0001) and more likely
to be female (78 versus 70% female, p= 0.040). The 114 class II
obese patients had a mean BMI of 50.1 kg/m2 (SD= 10.0, range:
35.0 kg/m2–78.3 kg/m2), a mean age of 44 years (SD= 10.8), and
79% were female.
Of the 24 individual symptom questions, 18 had a higher fre-
quency in the class II and III obesity group as compared to the
normal weight group (p< 0.05, Table 1). Significant associations
were found for three of the five oral symptom questions, two of the
three dysphagia questions, four of the five reflux questions, both of
the abdominal pain questions, and seven of the nine bowel habits
questions.
When combining questions into symptom groups, the preva-
lence of any symptom within each of the five groups was higher in
the class II obese group (Figure 1). Oral symptoms were present in
57% of the obese group versus 38% of the normal weight patients
(p= 0.0016). Dysphagia symptoms were present in 32% of the
obese group versus 17% in those with normal weight (p= 0.0038).
Reflux was significantly higher in obese patients compared to nor-
mal weight patients (79 versus 48%, p< 0.0001). Forty percent of
the obese subjects experienced abdominal pain symptoms as com-
pared to 25% of the normal weight patients (p= 0.0088). Finally,
altered bowel habits were more common in the obese group (82%)
as compared to the normal weight group (61%, p< 0.0001).
After adjusting for age and gender, the prevalence of symptoms
remained higher in the class II obese group for all of the symptom
groups (Table 3). Those in the obese group were 2.28 times more
likely to have oral symptoms [95% CI= (1.38, 3.78), p= 0.0013],
2.90 times more likely to have dysphagia [95% CI= (1.58, 5.33),
p= 0.0006], 3.77 times more likely to have reflux [95% CI= (2.16,
6.59), p< 0.0001], 1.73 times more likely to have abdominal pain
[95% CI= (1.02, 2.94), p= 0.042], and 2.79 times more likely to
have altered bowel habits [95% CI= (1.55, 5.01), p< 0.0001].
DISCUSSION
Both population-based (8–10) and hospital- or office-based (11,
12) studies have demonstrated an increase in the prevalence of
GI symptoms in obese individuals. The most extensively studied
are esophageal symptoms, which include gastroesophageal reflux
(often used interchangeably with heartburn), which also occurs in
approximately 40% of individuals in the general population (13).
Other esophageal symptoms include the regurgitation of solids or
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Table 1 | GI symptom survey responses by symptom category (114 obese patients and 182 normal weight patients).
Group Never (%) Rarely (%) Occasionally (%) Frequently (%) p-value
ORAL SYMPTOMS
Do you get painful mouth ulcers? Normal 57 34 9 1 0.355
C II and III obese 59 36 5 0
Do you get sore or swollen tongue? Normal 88 10 2 1 0.015
C II and III obese 76 18 4 1
How often do you get dental work like filling treatments,
root canal treatments, etc?
Normal 16 63 17 3 0.570
C II and III obese 18 56 23 4
Do you get bleeding gums? Normal 51 36 12 2 0.0003
C II and III obese 36 36 18 11
Do you often get sensation of bitter or sour taste in your
mouth?
Normal 77 15 6 2 <0.0001
C II and III obese 58 19 15 8
DYSPHAGIA
Do you experience trouble swallowing liquid food? Normal 87 7 3 2 0.538
C II and III obese 79 17 4 0
Do you have trouble swallowing solid foods? Normal 75 15 7 2 0.047
C II and III obese 66 18 14 3
Do you experience gagging or frequent need to clear
throat?
Normal 65 23 9 3 0.0010
C II and III obese 50 24 16 11
REFLUX
How often do you experience nausea? Normal 29 55 11 5 0.0093
C II and III obese 21 46 27 6
Do you vomit or throw up after eating? Normal 88 10 2 0 0.218
C II and III obese 83 13 4 0
How often do you experience heartburn also called reflux? Normal 36 41 14 10 <0.0001
C II and III obese 22 30 28 20
Do you often get sensation of bitter or sour taste in your
mouth?
Normal 77 15 6 2 <0.0001
Obese 58 19 15 8
How often do you get belching or burping? Normal 22 46 21 12 <0.0001
C II and III obese 10 29 32 29
ABDOMINAL PAIN
Do you get abdominal pain, discomfort or cramping within
2 h of eating?
Normal 58 25 9 9 0.010
C II and III obese 40 30 23 7
Do you experience abdominal pain, discomfort or cramping
when you are hungry?
Normal 67 21 9 3 0.0017
C II and III obese 49 27 19 5
BOWEL HABITS
How often do you get diarrhea (more than three stools in a
day) or stools with loose consistency?
Normal 27 53 13 6 <0.0001
C II and III obese 16 38 29 18
Do you get fecal urgency (having to rush to have a bowel
movement?
Normal 41 44 10 5 <0.0001
C II and III obese 21 33 31 15
Have you ever lost control of your stools? Normal 82 13 4 1 <0.0001
C II and III obese 57 32 8 4
Do you underclothes get soiled by feces? Normal 81 14 5 0 0.0002
C II and III obese 63 24 8 5
Do you often get constipation (less than three bowel
movements per week)?
Normal 45 31 13 11 0.771
C II and III obese 45 33 13 9
(Continued)
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Table 1 | Continued
Group Never (%) Rarely (%) Occasionally (%) Frequently (%) p-value
Do you get abdominal bloating? Normal 35 38 14 13 0.0014
C II and III obese 22 28 35 15
How often have you had rectal bleeding in last 1 year? Normal 74 18 6 2 0.0014
C II and III obese 58 19 19 3
Do you pass excessive flatus? Normal 28 36 21 15 0.0005
C II and III obese 15 28 31 26
How would you rate your use of laxatives or enema? Normal 82 13 4 1 0.724
C II and III obese 85 10 2 3
Table 2 | Description of the normal weight and obese study
populations.
Normal weight Class II and III obese
N =182 N =114
Gender Male 22% (n=40) 21% (n=24)
Female 78% (n=142) 79% (n=90)
Age Mean (SD) 50.8 (11.1) 44.0 (10.8)
Range (min, max) (20, 64) (19, 64)
BMI Mean (SD) 22.1 (1.7) 50.1 (10.0)
Range (min, max) (18.5, 25.0) (35.0, 78.3)
sour liquids, globus, chest pain, dysphagia, dry cough, and throat
pain (8). Our study, which comprised morbidly obese individu-
als (mean BMI >50 kg/m2), confirms these findings. This is not
surprising since individuals with a BMI >30 kg/m2 have a three-
fold increase in the odds of having reflux symptoms (14). This
finding has been confirmed repeatedly including in the recent Pro-
gression of Gastroesophageal Reflux Disease study, which demon-
strated that there was increased severe heartburn, regurgitation,
and esophagitis with higher BMI, with regurgitation being more
frequent than heartburn (15) and in two meta-analyses (16, 17).
There was a trend toward greater GERD symptoms in individuals
with a BMI >30 kg/m2 (pooled adjusted odds ratio of 1.94 com-
pared to1.43 for individuals with a BMI of 25–30 kg/m2) when
GERD was diagnosed by a validated questionnaire or endoscopy
findings (16). Not only is heartburn more common in the obese
individual (32.6 versus 18.8% in normal weight controls) so is
endoscopic evidence of hiatal hernia and gastritis (11). In contrast,
in massive obesity no association with heartburn was found (18).
The mechanism of upper GERD symptoms in obesity remains
conjectural partly because there are limited studies addressing this
(13). While basal lower esophageal sphincter (LES) pressure is
similar in morbidly obese individuals and normal weight individ-
uals (19), the frequency of transient lower esophageal sphincter
relaxation (TLESR) is increased with increasing BMI and waist
circumference (20), suggesting that waist circumference plays a
role in GERD in obesity. Additionally, increased intra-abdominal
pressure (21), increased gastroesophageal pressure gradient, hiatal
hernia (11), altered visceral sensitivity and increased gastric basal
pressure (22) all probably play a variable role. We did not evaluate
the effect of weight circumference and waist to hip ratio in our
patients.
There are less clear mechanistic studies on GI symptoms such as
chest pain, bloating, and post-prandial fullness. The role that pro-
inflammatory cytokines play in obesity, i.e., TNF-α, IL-6, IL-1, and
leptin (23) and the concomitant decrease in the pro-inflammatory
cytokine, adiponectin (24) may play in esophageal contractility
and increased incidence of esophagitis is unclear as is their role in
gastric motility, gastritis, small and large bowel function in obesity.
It is possible that estrogens implicated in more frequent TLESRs
(25) could skew the results of GERD-related symptoms in our pre-
dominantly female population (79% female versus 21% male in
obese subjects and 78% female and 22% male in normal weight
subjects) but age and gender corrected analysis of our data did not
alter our results.
In keeping with published reports, our obese patients reported
more frequent nausea, abdominal pain, bloating, diarrhea, and
flatulence compared to normal weight individuals (9, 26). We did
not distinguish between upper and lower abdominal pain as many
patients had difficulty making this distinction. The mechanism
of abdominal and bowel symptoms (Tables 1 and 3; Figure 1)
is unclear and studies are few and data conflicting. It has been
suggested that alteration in gastric emptying, gastric capacity, and
gastric accommodation may play a role (27, 28). The role, if any
of pro-inflammatory cytokines in abdominal pain, early satiety,
flatulence, and diarrhea have not been studied. It is reasonable to
assume that they do play a role in intestinal motility in general and
not just in esophageal muscle contractility (23).
The prevalence of dysphagia has been reported to be approxi-
mately 10% and globus 8% in patients being evaluated for bariatric
surgery (29). In our subjects, the prevalence of dysphagia to solids
was 3% in obese subjects compared to 2% in normal weight indi-
viduals (p= 0.047). There is no obvious reason for the lower
prevalence of dysphagia in our obese patients. Dysphagia to liq-
uids, a symptom not reported in other studies, was higher in
normal weight individuals although it did not reach statistical
significance (p= 0.538).
Obese individuals in our study had similar prevalence of con-
stipation and laxative use as normal weight individuals. The data
in the literature are conflicting with regard to constipation where
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FIGURE 1 | Percent of normal weight (N =182) and class II and III obese (N =114) patients with occasional/frequent symptoms in each symptom
group.
Table 3 | Multivariate regression results for presence of any symptom
within the symptom group.
Symptom group Adjusteda OR for
class II and III obesity
95% CI p-value
Oral symptoms 2.28 1.38, 3.78 0.0013
Dysphagia 2.90 1.58, 5.33 0.0006
Reflux 3.77 2.16, 6.59 <0.0001
Abdominal pain 1.73 1.02, 2.94 0.042
Bowel habits 2.79 1.55, 5.01 0.0006
aAdjusted for age and gender.
some studies have found no relationship between BMI and con-
stipation (30), while others have found a higher prevalence of
constipation in obese individuals (31) and those who were binge
eaters (32).
Diarrhea, fecal urgency, and incontinence were more com-
monly reported in our obese subjects, a finding consistent with
that reported in both population – as well as clinic-based studies
(9, 29, 33). Decreased colonic compliance and colonic sensation
in overweight individuals and decreased transit time in those with
a BMI >30 kg/m2 could play a role in the pathogenesis of these
symptoms (34).
The role of nutrient-sensing mechanisms in the GI tract (taste
receptors) (35), their interplay with peptides such as glucagon-like
peptide one, glucagon, neuropeptide Y, peptide YY, ghrelin, and
oxyntomodulin (36) among others and their effect, if any, on sati-
ety, gut motility, nutrient absorption, gut–brain signaling via vagal
afferent neurons (37), and GI symptoms are yet to be explored.
There are no previous reports of oral symptoms in obese indi-
viduals compared to normal weight individuals. A sore tongue or
a sensation of a swollen tongue (p< 0.015) and bleeding gums
(p< 0.003) occurred more frequently in our obese patients. The
increased sensation of a bitter taste or sour taste in the mouth
is consistent with “water brash,” a symptom of gastroesophageal
reflux, which occurs more frequently in obese individuals. The
mechanism of the increased prevalence of oral symptoms could be
related to micronutrient deficiencies, but this remains speculative
since we did not measure any micronutrient level.
Our study has several strengths in that: (i) we were able to doc-
ument the increased prevalence of GI symptoms in a clinic-based
population, confirming the data on GI symptoms derived largely
from population studies. (ii) We describe for the first time that
oral symptoms (swollen tongue and bleeding gums) occur more
frequently in obese patients. (iii) While there was a preponderance
of females in our study, and females are known to have more func-
tional bowel disease compared to males (38) even after adjusting
for age and gender the results of our study do not change (Table 3).
(iv) We did not cluster symptoms based on diagnosis so that clus-
tering did not skew our data. For example, a higher irritable bowel
syndrome score may be reflected in a higher abdominal pain score.
There are several limitations to our study: (i) we did not
use validated questionnaires such as the gastroesophageal reflux
questionnaire (8) or the bowel disease questionnaire (39). These
questionnaires were designed to establish a diagnosis of gastroe-
sophageal reflux or functional bowel disease in population cohorts;
this was not the purpose of our study. Besides, our questionnaire
did incorporate most of the questions found in the validated ques-
tionnaires. (ii) We did not evaluate anxiety and depression in our
subjects. These conditions are associated with higher somatic com-
plaints including GI symptoms. (iii) The prevalence of diabetes
and vascular disease, among other chronic diseases, is higher in
obesity. These diseases are known to be associated with abdomi-
nal symptoms and could have confounded our results. (iv) We did
not take into account the influence of medications on GI symp-
toms used to treat the chronic diseases that these subjects had. (v)
Our population was predominantly Caucasian, so the results of
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our study may not be generalizable to individuals of different eth-
nic backgrounds and possibly different food habits. (vi) A response
rate of 28% in our study does not automatically imply that the fre-
quencies are not accurate. They do have the potential to have more
error but equally they could be accurate. Higher response rates of
54–68% are found in the literature in some studies. The higher
response rate appears to be dependent on the level of education of
the respondents. Other studies have shown a response rate of 26%
for mail surveys, which is similar to the response rate in our study
(40). This is in contrast to faxed and electronic surveys, which
have higher response rates. It is important to bear in mind that the
response rate indirectly reflects non-respondent bias. It has been
suggested that more attention be paid to assessments of bias, and
less to response rate (41). We therefore feel that our response rate
does not detract from the validity of the study.
In conclusion, this study demonstrates that several GI symp-
toms are more commonly seen in obese individuals compared
to normal weight individuals with similar comorbidities. Better
understanding of the mechanism of these symptoms may be valu-
able in offering the appropriate treatment, i.e., surgical versus
medical particularly as medical therapeutic options increase (36).
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